Form 4: Eliem Therapeutics Executive Emily Pimblett Reports Stock Transactions
SEC Form 4 Filing
Emily Pimblett, Chief Accounting Officer of Eliem Therapeutics, reports the conversion of restricted stock units and subsequent sale of shares to cover tax obligations.
Summary
- On June 18, 2024, Emily Pimblett converted 5,000 restricted stock units (RSUs) into 5,000 shares of Eliem Therapeutics common stock.
- On June 20, 2024, Pimblett sold 1,245 shares of common stock at a price of $7.2145 per share.
- The sale was to cover tax withholding obligations related to the vesting and settlement of the RSUs.
- Following these transactions, Pimblett directly owns 3,755 shares of Eliem Therapeutics common stock and 35,000 restricted stock units.
Sentiment
Score: 5
Explanation: The document is a routine disclosure of stock transactions by an insider, with no inherent positive or negative sentiment.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership.
Key Dates
| Date | Description |
|---|---|
| 03/18/2024 | March 2024 Vesting Commencement Date for RSUs |
| 06/18/2024 | Conversion of 5,000 Restricted Stock Units to Common Stock |
| 06/20/2024 | Sale of 1,245 shares of Common Stock at $7.2145 |
| 06/21/2024 | Date of Form 4 signature |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.